中国人民解放军总医院
Chinese PLA General Hospital
名字里带这所大学的医院合在一起算,再加上只署大学名称的论文和试验。
只反映研究活动,不代表医疗水平,也不是医疗建议。 使用说明
鼻咽癌
Nasopharyngeal carcinoma2021–2025年中国大陆共有 2,375 篇该病的 PubMed 英文论文,这里牵头了其中 8 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(23.4%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 8
- 牵头的试验
- 1
- 占中国试验的比例
- 0.2%
- 占全球论文的比例
- 0.2%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- The Acute Toxicities and Efficacy of Concurrent Chemotherapy With Docetaxel Plus Cisplatin, or Docetaxel, or Cisplatin and Helical Tomotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomiz
- Cutaneous metastasis secondary to nasopharyngeal carcinoma: a case report.
- Sparing submandibular gland to alleviating acute xerostomia in patients with nasopharyngeal carcinoma treated with helical tomotherapy: Evaluation by diffusion kurtosis imaging.
- Comparison of the pre-treatment functional MRI metrics' efficacy in predicting Locoregionally advanced nasopharyngeal carcinoma response to induction chemotherapy.
- CircCGNL1 Suppresses Nasopharyngeal Carcinoma Progression by Targeting IGF2BP3 and Inhibiting AKT/mTOR Signaling.
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025年中国大陆共有 2,923 篇该病的 PubMed 英文论文,这里牵头了其中 27 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(6.9%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 27
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.6%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 st
- Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).
- First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306.
- Spatial proteomic profiling elucidates immune determinants of neoadjuvant chemo-immunotherapy in esophageal squamous cell carcinoma.
- Long-term efficacy and predictors of pembrolizumab-based regimens in patients with advanced esophageal cancer in the real world.
ClinicalTrials.gov 上的试验6
- Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
- Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer
- A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors
- KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma
- A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
肝细胞癌
Hepatocellular carcinoma2021–2025年中国大陆共有 14,765 篇该病的 PubMed 英文论文,这里牵头了其中 184 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(5.5%)相比。
- 牵头的开放试验
- 6
- 牵头的研究论文
- 184
- 牵头的试验
- 29
- 占中国试验的比例
- 2.0%
- 占全球论文的比例
- 0.6%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.
- Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.
- The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis.
- High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy.
- Peripheral immune factors aiding clinical parameter for better early recurrence prediction of hepatocellular carcinoma after thermal ablation.
ClinicalTrials.gov 上的试验6
- Fusing Ultrasound and Magnetic Resonance Imaging to Intelligently Plan Highly Conformal Ablation Thermal Field for Hepatocellular Carcinoma
- PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma
- CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma
- Image Driven Hepatocellular Carcinoma Invasiveness Evaluation Research
- To Compare the Efficacy of Microwave Ablation and Laparoscopic Hepatectomy for Hepatocellular Carcinoma
- Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma
胃癌
Stomach cancer2021–2025年中国大陆共有 9,782 篇该病的 PubMed 英文论文,这里牵头了其中 140 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(3.9%)相比。
- 牵头的开放试验
- 6
- 牵头的研究论文
- 140
- 牵头的试验
- 28
- 占中国试验的比例
- 1.9%
- 占全球论文的比例
- 0.7%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- 177Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised
- Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.
- Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial.
- Diagnostic accuracy of linked colour imaging versus white light imaging for early gastric cancers: a prospective, multicentre, randomized controlled trial study.
- Effect of Postoperative ω-3 Fatty Acid Immunonutritional Therapy on NK Cell Gene Methylation in Elderly Patients with Gastric Cancer.
ClinicalTrials.gov 上的试验6
- Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer
- The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial
- EGPSS for Weight Management in an in Vivo Human Model
- Helicobacter Pylori Infection Status and Pathological Features for Predicting Gastric Cancer Biological Behavior and Prognosis: A Real-World Observational Study
- Prospective Observational Cohort Study
- Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer
肝母细胞瘤
Hepatoblastoma2021–2025年中国大陆共有 154 篇该病的 PubMed 英文论文,这里牵头了其中 3 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(13.6%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 3
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.7%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
视网膜母细胞瘤
Retinoblastoma2021–2025年中国大陆共有 301 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(12.0%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.2%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
骨肉瘤
Osteosarcoma2021–2025年中国大陆共有 2,257 篇该病的 PubMed 英文论文,这里牵头了其中 12 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(4.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 12
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.2%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Adamantinoma‑like Ewing Sarcoma of Head and Neck: A Clinicopathologic Study of Three Cases Including One EWSR1-Negative Case with NF1 Mutation.
- Neoadjuvant Chemotherapy and Expandable Prosthesis Reconstruction to Treat Osteosarcoma around the Knee in Children.
- Co-Delivery of Cisplatin and Curcumin via ROS-Responsive Nanoparticles to Activate the cGAS-STING Pathway for Osteosarcoma Metalloimmunotherapy.
- Unveiling the role of the extracellular matrix in the osteosarcoma tumor microenvironment through integrated transcriptomics and experimental validation.
- DOT1L suppressed the proliferation of osteosarcoma cell line via modulating SYK/EGFR/P53 and SHP2-induced STING-NLRP3-pyroptosis signaling.
ClinicalTrials.gov 上的试验1
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025年中国大陆共有 523 篇该病的 PubMed 英文论文,这里牵头了其中 7 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(6.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 7
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.4%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- The maximum transverse diameter: an effective indicator for predicting peroral en bloc retrieval rate of mesenchymal tumors after endoscopic resection.
- Application of through-the-scope twin clip for defect closure after gastric gastrointestinal stromal tumor transoral super minimally invasive surgery resection.
- Endoscopic resection for the treatment of gastric gastrointestinal stromal tumors: a retrospective study from a large tertiary hospital in China.
- Endoscopic resection of gastrointestinal stromal tumors.
- Endoscopic resection for the treatment of non-gastric gastrointestinal stromal tumors: A retrospective study from a large tertiary hospital in China.
ClinicalTrials.gov 上的试验6
- A Novel Two-Tooth Clip for ESD and EFTR of GIST
- A Study of HQP1351 in Patients With GIST or Other Solid Tumors
- Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
- A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
- A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
- A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
神经母细胞瘤
Neuroblastoma2021–2025年中国大陆共有 1,132 篇该病的 PubMed 英文论文,这里牵头了其中 1 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(8.8%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 1
- 牵头的试验
- 1
- 占中国试验的比例
- 2.4%
- 占全球论文的比例
- 0.02%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
多发性骨髓瘤
Multiple myeloma2021–2025年中国大陆共有 1,676 篇该病的 PubMed 英文论文,这里牵头了其中 5 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(4.8%)相比。
- 牵头的开放试验
- 2
- 牵头的研究论文
- 5
- 牵头的试验
- 5
- 占中国试验的比例
- 1.0%
- 占全球论文的比例
- 0.05%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- HLA-mismatched stem cell microtransplant prolonged overall survival and promoted immunological reconstitution for multiple myeloma.
- Percutaneous vertebroplasty combined with chemotherapy in the treatment of multiple myeloma patients with vertebral compression fractures.
- Clotrimazole inhibits growth of multiple myeloma cells in vitro via G0/G1 arrest and mitochondrial apoptosis.
- Magnetic Resonance Imaging combined with Computed Tomography in the Diagnosis of Multiple Myeloma and the Killing Effect of Doxorubicin Nano-drug Delivery System on Myeloma Cells.
- Upregulation of ATIC in multiple myeloma tissues based on tissue microarray and gene microarrays.
ClinicalTrials.gov 上的试验6
- Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
- Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
- Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma
- A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
- Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138
- Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
B 细胞急性淋巴细胞白血病
B-cell acute lymphoblastic leukaemia (B-ALL)2021–2025年中国大陆共有 225 篇该病的 PubMed 英文论文,这里牵头了其中 0 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(8.9%)相比。
- 牵头的开放试验
- 6
- 牵头的研究论文
- 0
- 牵头的试验
- 12
- 占中国试验的比例
- 4.7%
- 占全球论文的比例
- 0.0%
ClinicalTrials.gov 上的试验6
- Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia
- Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL
- BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL
- TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
- Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL
- Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen
再生障碍性贫血
Aplastic anaemia2021–2025年中国大陆共有 412 篇该病的 PubMed 英文论文,这里牵头了其中 1 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(17.2%)相比。
- 牵头的开放试验
- 1
- 牵头的研究论文
- 1
- 牵头的试验
- 3
- 占中国试验的比例
- 3.1%
- 占全球论文的比例
- 0.06%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
ClinicalTrials.gov 上的试验3
噬血细胞性淋巴组织细胞增生症
Haemophagocytic lymphohistiocytosis (HLH)2021–2025年中国大陆共有 399 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(22.3%)相比。
- 牵头的开放试验
- 1
- 牵头的研究论文
- 2
- 牵头的试验
- 1
- 占中国试验的比例
- 2.1%
- 占全球论文的比例
- 0.1%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文2
- Central nervous system Aspergillus fumigatus infection with subarachnoid haemorrhage secondary to hemophagocytic lymphohistiocytosis: a rare case report.
- Case Report: Chronic inflammatory demyelinating polyradiculoneuropathy rather than hemophagocytic lymphohistiocytosis-the initial phenotype of PRF1 gene mutation.
视神经脊髓炎谱系疾病
Neuromyelitis optica spectrum disorder (NMOSD)2021–2025年中国大陆共有 485 篇该病的 PubMed 英文论文,这里牵头了其中 12 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(10.5%)相比。
- 牵头的开放试验
- 2
- 牵头的研究论文
- 12
- 牵头的试验
- 4
- 占中国试验的比例
- 5.1%
- 占全球论文的比例
- 0.6%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Nomogram for the prediction of relapse factors in patients with neuromyelitis optica spectrum disorder during rituximab treatment.
- Rituximab maintenance treatment outcomes in patients with relapsing neuromyelitis optica spectrum disorder: a monocentric retrospective analysis.
- Safety and efficacy of plasma exchange treatment in children with AQP4-IgG positive neuromyelitis optica spectrum disorder.
- Bilateral parafalcine cortical and leptomeningeal impairment in MOG antibody disease and AQP4 neuromyelitis optica.
- Lower motor neuron involvement in patients with neuromyelitis optica spectrum disorders.
ClinicalTrials.gov 上的试验6
- Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study
- The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.
- A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20
- Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders
- A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
IgG4相关性疾病
IgG4-related disease2021–2025年中国大陆共有 246 篇该病的 PubMed 英文论文,这里牵头了其中 5 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(19.1%)相比。
- 牵头的开放试验
- 2
- 牵头的研究论文
- 5
- 牵头的试验
- 3
- 占中国试验的比例
- 7.0%
- 占全球论文的比例
- 0.4%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Clinical phenotypes and prognosis of IgG4-RD patients with allergy history: A retrospective cohort study.
- The co-occurrence of IgG4-related disease and malignancy: insights from a prospective cohort study.
- Assessing IgG4-related autoimmune pancreatitis with contrast-enhanced ultrasonography based on time-intensity curve: a single-centre prospective study.
- A case of IgG4-related ophthalmic disease after SARS-CoV-2 vaccination: case report and literature review.
- Clinical value of plasmablasts in predicting disease relapse in patients with IgG4-related disease.
ClinicalTrials.gov 上的试验5
- Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease
- Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease
- A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
- Leflunomide for Maintenance of Remission in IgG4 Related Disease
- A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
重症肌无力
Myasthenia gravis2021–2025年中国大陆共有 499 篇该病的 PubMed 英文论文,这里牵头了其中 4 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(6.6%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 4
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.2%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文4
- Autonomic dysfunction detected by skin sympathetic response in Lambert-Eaton myasthenic syndrome: a case report.
- Circulating inflammatory cytokines and the risk of myasthenia gravis: a bidirectional Mendelian randomization study.
- Myasthenia gravis with amyotrophic lateral sclerosis with positive anti-Hu antibody: a rare co-existence.
- Plasma lncRNA LOC338963 and mRNA AP3B2 are upregulated in paraneoplastic Lambert-Eaton myasthenic syndrome.
烟雾病
Moyamoya disease2021–2025年中国大陆共有 356 篇该病的 PubMed 英文论文,这里牵头了其中 46 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(19.9%)相比。
- 牵头的开放试验
- 1
- 牵头的研究论文
- 46
- 牵头的试验
- 2
- 占中国试验的比例
- 6.1%
- 占全球论文的比例
- 3.7%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Noninvasive Assessment of the Risk Features of Hemorrhage in Moyamoya Disease Using 7T MRI.
- Champagne bottle neck sign predicts intracranial hemorrhage in Moyamoya disease: A long-term follow-up study.
- Optimizing Surgical Timing to Reduce Stroke Risk in Pediatric Moyamoya Disease.
- Clinical significance of postoperative collateral circulation formation in long-term prognosis and stroke events after EDAS in adults with moyamoya disease.
- Long-Term Outcomes in Patients With Hemorrhagic Moyamoya Disease Combined With Hypertension After Encephaloduroarteriosynangiosis.
ClinicalTrials.gov 上的试验6
- The Evolution and Prognosis of Moyamoya Disease
- Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
- Predicative Value of Multimodal MRI in Moyamoya Disease
- Safety and Efficacy of RIC in Pediatric Moyamoya Disease Patients Treated With Revascularization Therapy
- Safety and Efficacy of Remote Ischemic Conditioning Combined EDAS on Ischemic Moyamoya Disease
- Effect of Surgical Revascularization on Hemorrhagic Moyamoya Disease
肝包虫病
Hepatic echinococcosis2021–2025年中国大陆共有 152 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(32.2%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.4%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文2
- Clinical value of the semi-quantitative parameters of 18F-fluorodeoxyglucose PET/CT in the classification of hepatic echinococcosis in the Qinghai Tibetan area of China.
- Ultrasound identification of hepatic echinococcosis using a deep convolutional neural network model in China: a retrospective, large-scale, multicentre, diagnostic accuracy study.
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025年中国大陆共有 989 篇该病的 PubMed 英文论文,这里牵头了其中 3 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(4.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 3
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.08%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文3
- Asymptomatic thrombocytopenia after nintedanib initiation in a patient with progressive pulmonary fibrosis: a case report and review of literature.
- Supramolecular Nanofibers Ameliorate Bleomycin-Induced Pulmonary Fibrosis by Restoring Autophagy.
- Features of transbronchial lung cryobiopsy-diagnosed fibrotic hypersensitivity pneumonitis.
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025年中国大陆共有 779 篇该病的 PubMed 英文论文,这里牵头了其中 20 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(8.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 20
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.3%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- The difference between cystatin C- and creatinine-based estimated glomerular filtration rate and survival in amyotrophic lateral sclerosis: a population-based cohort study.
- Fecal microbiota transplantation significantly improved respiratory failure of amyotrophic lateral sclerosis.
- Prognostic value of geriatric nutritional risk index in patients with amyotrophic lateral sclerosis.
- Quantitative association between lead exposure and amyotrophic lateral sclerosis: a Bayesian network-based predictive study.
- Time of symptoms beyond the bulbar region predicts survival in bulbar onset amyotrophic lateral sclerosis.
脊髓性肌萎缩症
Spinal muscular atrophy2021–2025年中国大陆共有 55 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(29.1%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.4%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文2
ClinicalTrials.gov 上的试验3
- Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III
- Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients
- Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients
法布雷病
Fabry disease2021–2025年中国大陆共有 73 篇该病的 PubMed 英文论文,这里牵头了其中 3 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(12.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 3
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.4%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文3
- Pathogenicity of novel GLA gene missense mutations in Fabry disease and the therapeutic impact of migalastat.
- Correlation of enzyme activities and genotype with clinical manifestations in Chinese patients of different sexes with classical and late-onset Fabry disease.
- The evolution of the initial manifestations and renal involvement of chinese patients with classical and late-onset Fabry disease at different sexes and ages.
庞贝病
Pompe disease2021–2025年中国大陆共有 30 篇该病的 PubMed 英文论文,这里牵头了其中 1 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(6.7%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 1
- 牵头的试验
- 1
- 占中国试验的比例
- 11.1%
- 占全球论文的比例
- 0.3%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
ClinicalTrials.gov 上的试验3
- Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug
- Clinical Exploration of Adeno-associated Virus (AAV) Expressing Human Acid Alpha- Glucosidase (GAA) Gene Therapy for Patients With Infantile-onset Pompe Disease
- Evaluation of the Safety and Efficacy of Infantile-onset Pompe Disease Gene Therapy Drug
杜氏肌营养不良
Duchenne muscular dystrophy2021–2025年中国大陆共有 213 篇该病的 PubMed 英文论文,这里牵头了其中 5 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(10.8%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 5
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.2%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Association between triglycerides and remnant cholesterol levels and spine bone mineral density in Duchenne muscular dystrophy.
- Current care practices for patients with Duchenne muscular dystrophy in China.
- Generation and differentiation of an induced pluripotent stem cell line (FMCPGHi006-A) from a patient with Duchenne muscular dystrophy carrying exons 42-43 deletion in the DMD gene.
- Mechanisms of cardiomyopathy in duchenne muscular dystrophy: A study using pluripotent stem cells derived from patients with severe and mild motor impairment.
- Genotype characterization and delayed loss of ambulation by glucocorticoids in a large cohort of patients with Duchenne muscular dystrophy.
ClinicalTrials.gov 上的试验3
- Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)
- Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)
- Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)
IgA 肾病
IgA nephropathy2021–2025年中国大陆共有 736 篇该病的 PubMed 英文论文,这里牵头了其中 17 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(9.4%)相比。
- 牵头的开放试验
- 1
- 牵头的研究论文
- 17
- 牵头的试验
- 1
- 占中国试验的比例
- 0.9%
- 占全球论文的比例
- 1.0%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- C3 glomerulopathy associated with mycoplasma pneumoniae infection and positive IgA staining.
- External Validation of the International IgA Nephropathy Prediction Tool in Older Adult Patients.
- Clinical relevance of glomerular C4d deposition in children with early IgA nephropathy or Henoch-Schönlein purpura nephropathy.
- Serum levels of galactose-deficient IgA1 in Chinese children with IgA nephropathy, IgA vasculitis with nephritis, and IgA vasculitis.
- Development and validation of a single-nephron estimated glomerular filtration rate model to predict disease progression in IgA nephropathy.
ClinicalTrials.gov 上的试验4
- Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.
- TESTING -ON Post-Trial ObservatioNal Cohort Study
- Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
- Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)
成骨不全症
Osteogenesis imperfecta2021–2025年中国大陆共有 99 篇该病的 PubMed 英文论文,这里牵头了其中 0 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(17.2%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 0
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.0%
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025年中国大陆共有 300 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(12.0%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 3
- 占中国试验的比例
- 6.0%
- 占全球论文的比例
- 0.2%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文2
ClinicalTrials.gov 上的试验5
- Phase I/II Trial of Human Umbilical Cord Mesenchymal Stromal Cells for UDCA-Refractory Primary Biliary Cholangitis
- Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA
- Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis
- Performance of Scoring Systems in Chinese Patients With Primary Biliary Cholangitis (PBC) on Ursodeoxycholic Acid
- Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis
家族性腺瘤性息肉病
Familial adenomatous polyposis2021–2025年中国大陆共有 59 篇该病的 PubMed 英文论文,这里牵头了其中 0 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(10.2%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 0
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.0%